SPOTLIGHT: Novartis plans Phase III trial


Vectura is touting an announcement from Novartis that it will begin a late-stage trial of a new COPD therapy in 2007 that incorporates a drug Vectura developed. Novartis expects to ask for marketing approval of QVA149--a combinatorial therapy--in 2010. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.